News | 15 April 2026
FDA presses 2,200+ companies to fix missing clinical trial results
Move amid evidence of widespread reporting gaps
Move amid evidence of widespread reporting gaps
Backed by funding from an NIHR Doctoral Award, the guidance is focused on spotting abdominal tumours
The study’s multi-technology design is intended to improve reproducibility, strengthen regulatory-grade evidence generation
GoodRx at a starting price of $149 per month—aligned with the lowest available discounted cash price at launch. The rollout includes nationwide pharmacy access
Panacea Biotec receives LoA from CMSS
A brand from Opella will be part of the official NASA astronaut formulary
The new test offers a minimally invasive blood-based approach to tracking neurological damage, measuring neurofilament light chain
The campaign builds on the three-year partnership unveiled earlier this season
At the centre of this shift is Eli Lilly and Company, whose latest investments in China and Japan are helping redefine the next phase of GLP-1 supply strategy
No adverse events reported; recall involves 5 mg 500-count bottles in the US market
The three-day conference is expected to bring together more than 3,000 physiotherapists, clinicians, researchers, academicians, and students
The partnership aims to fuse antibody-drug conjugation (ADC) technology with targeted protein degradation
Each program will rely on partnerships between Novartis teams and local networks—including health authorities, community organizations and private sector groups
Novo Nordisk continues to position Wegovy as a cornerstone of its obesity treatment portfolio
The once-daily oral medication is approved for adults with obesity or overweight who have weight-related medical conditions
Routine regulatory filing confirms completion of demat and share transfer compliances for March quarter
The improved score reflects a stronger ESG profile for the Ahmedabad-based drugmaker
The FDA clearance of Zeto New Wave marks the company’s third cleared device, alongside Zeto WR19 and Zeto ONE
The presentations will showcase previously undisclosed data highlighting the expanding potential of Actinium’s Ac-225 radiotherapy platform across both solid tumors and hematologic malignancies
The initiative is aimed at strengthening the district-level screening and chronic disease management infrastructure
Subscribe To Our Newsletter & Stay Updated
